Elsevier, Cell Press Demo the “Article of the Future”



By Kevin Davies

July 20, 2009 | In a further sign that academic publishing is looking to embrace the opportunities provided by multimedia, the giant Dutch publisher Elsevier and its flagship subsidiary Cell Press have introduced a demo of the “Article of the Future” – a new prototype for publishing scientific articles that features enhanced graphical navigation, integrated multimedia, and a non-linear structure.

The “Article of the Future” is billed as “an ongoing collaboration with the scientific community to redefine how a scientific article is presented online.” This week, the first two article prototypes were launched at beta.cell.com, where viewers are invited to comment on the overall design and functionality.

“The genesis of the ‘Article of the Future’ project came from a challenge to redesign from scratch how to most effectively structure and present the content of a traditional scientific article in an online environment,” said Emilie Marcus, editor-in-chief of Cell, the leading molecular biology journal and cornerstone of Cell Press.

“The rapid pace of technological advancements means this will undoubtedly be an evolving design, but we are happy to be able to address some key reader and author pain points such as the integration of supplemental data with these initial prototypes,” said Marcus.

Among the distinguishing features of the prototype articles is a hierarchical presentation of text, figures and tables. This enables readers to address the information in multiple ways depending on their own interests and expertise, rather than approach the manuscript in a traditional linear fashion. Each article also contains bulleted highlights and a graphical abstract, to assist readers quickly grasp the central message of the paper. The graphical abstract encourages browsing, one of the advantages of printed journals.

Other features in the beta demonstrations include embedded podcasts, featuring an interview between a Cell Press editor and the article’s lead author. That wouldn’t be feasible for every published paper, but the same idea could be used to allow authors to present their own supplementary multimedia presentations (as seen for example on SciVee.tv.)

In addition, the beta models include a figure that contains clickable areas to serve as a navigational device to other sections of the article. The methods section contains basic and extended views in the event that readers wish to find the necessary depth of detail to replicate the experiment. All main and supplementary figures can be viewed together and selected. Real-time reference analyses provide the ability to explore references along with their updated citation statistics.

The prototypes were developed by the Cell Press in conjunction with Elsevier’s User Centered Design group. While accessible summaries (a feature introduced by Nature Medicine more than a decade ago and continued by the Public Library of Science), podcasts and other features are not necessarily unique, it is noteworthy to see one of the largest academic publishers moving aggressively to implement such tools. Elsevier eventually plans to roll out the results of this experiment across its entire portfolio of 2,000 journals on ScienceDirect.

“Together with the 2009 Elsevier Grand Challenge, the ‘Article of the Future’ project forms part of Elsevier’s commitment to collaborating with our scientific community on content innovation,” said IJsbrand Jan Aalbersberg, VP content innovation for Elsevier Science & Technology Journal Publishing, “These tools… are central to driving innovation in scientific publishing and represent our investment in the future of research, enabling scientists all over the world to access, interpret, and create better science more efficiently.”

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi whp 2
Managing the Modern Genomics Data Flood
Sponsored by SGI

Managing and storing the perfect storm of multi-disciplined data pouring from next generation sequencers and other omics instruments is a central challenge in life sciences. Discover in this paper how the SGI ArcFiniti storage solution, optimized for unstructured genomics and life sciences data can: 

  • Reduce costs, proactively protect data integrity, and deliver the high performance I/O required for genomics data processing and analysis.  
  • Effectively manage capacities from 156TB to 1.4PB as a disk based, integrated hardware and software platform 


sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .